SCHEMBL25323757

SCHEMBL25323757

N#Cc1ccncc1OCc1cccc(C(F)F)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.37
ALOX5AP P20292 2/20 0.36
FEN1 P39748 2/20 0.36
FFAR1 O14842 1/20 0.35
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPK14 Q16539 1/20 0.33
TGFBR1 P36897 2/20 0.32
NOTUM Q6P988 1/20 0.32
CYP19A1 P11511 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
RXRA P19793 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32
PIP4K2A P48426 1/20 0.32
AAK1 Q2M2I8 1/20 0.31
SGMS2 Q8NHU3 1/20 0.31
KCNH2 Q12809 1/20 0.31
FNTA P49354 1/20 0.31
FNTB P49356 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29530232 1.00 HTT (0.37) HTTALOX5APFEN1FFAR1ALDH1A1
SCHEMBL25319653 0.84 HTT (0.39) HTTALOX5APFEN1FFAR1ALDH1A1
SCHEMBL4766847 0.84 FFAR1 (0.45) HTTFFAR1ALDH1A1SMN1; SMN2TGFBR1
SCHEMBL29529877 0.79 LOXL2 (0.38) RXRAGRIN1GRIN2BKCNH2
SCHEMBL25321602 0.79 CLK1 (0.38) HTTFFAR1ALDH1A1SMN1; SMN2NCOA3
SCHEMBL25320465 0.79 LOXL2 (0.38) RXRAGRIN1GRIN2BKCNH2
SCHEMBL29102328 0.78 TGFBR1 (0.35) TGFBR1RXRAGRIN1GRIN2B
SCHEMBL25320336 0.77 IDH1 (0.39) HTTFFAR1ALDH1A1SMN1; SMN2NOTUM
SCHEMBL25320659 0.76 ALDH1A1 (0.38) HTTALOX5APFEN1FFAR1ALDH1A1
SCHEMBL29530250 0.76 ALDH1A1 (0.38) HTTALOX5APFEN1FFAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2023-11-16 US disclosed
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2023-11-16 US disclosed
CN-116997549-A Pyrrolo [3,2-C ] pyridin-4-one derivatives for the treatment of cancer 蝎子疗法股份有限公司 2023-11-03 CN disclosed
EP-4217070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Scorpion Therapeutics, Inc. (US) 2023-08-02 EP disclosed
WO-2022066734-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER SCORPION THERAPEUTICS, INC. (US) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ERBB2, EGFR, ERBB3 HTT 2235/4885ALOX5AP 2807/4885FEN1 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.